Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 12/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.57 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27970706 | 1.00 | FAAH (0.65) | FAAHSMN1; SMN2SLC6A5PSMB5MEN1 | |
| SCHEMBL20503295 | 0.98 | FAAH (0.67) | FAAHSMN1; SMN2SLC6A5PSMB5MEN1 | |
| SCHEMBL9829925 | 0.98 | FAAH (0.67) | FAAHSMN1; SMN2SLC6A5PSMB5MEN1 | |
| SCHEMBL2370383 | 0.98 | FAAH (0.67) | FAAHSMN1; SMN2SLC6A5PSMB5MEN1 | |
| SCHEMBL2370661 | 0.98 | FAAH (0.67) | FAAHSMN1; SMN2SLC6A5PSMB5MEN1 | |
| SCHEMBL27970567 | 0.98 | FAAH (0.67) | FAAHSMN1; SMN2SLC6A5PSMB5MEN1 | |
| SCHEMBL9829935 | 0.98 | FAAH (0.67) | FAAHSMN1; SMN2SLC6A5PSMB5MEN1 | |
| SCHEMBL25052762 | 0.97 | FAAH (0.64) | FAAHSMN1; SMN2SLC6A5PSMB5MEN1 | |
| SCHEMBL12349998 | 0.87 | FAAH (0.81) | FAAHSMN1; SMN2SLC6A5MEN1KMT2A | |
| SCHEMBL12350003 | 0.87 | FAAH (0.81) | FAAHSMN1; SMN2SLC6A5MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2756067-B1 | MICROCAPSULE COMPOSITIONS COMPRISING PH TUNEABLE DI-AMIDO GELLANTS | PROCTER & GAMBLE (US) | 2017-06-14 | — | — | EP | claimed |
| EP-2365052-B1 | pH tuneable-gellant for use in consumer product compositions | PROCTER & GAMBLE (US) | 2016-07-13 | — | — | EP | claimed |
| EP-2365053-B1 | Liquid detergent compositions comprising pH tuneable amido-gellants, and processes for making | PROCTER & GAMBLE (US) | 2016-04-27 | — | — | EP | claimed |
| US-9271912-B2 | Personal care compositions comprising a pH tuneable gellant and methods of using | THE PROCTER & GAMBLE COMPANY (US) | 2016-03-01 | — | — | US | claimed |
| CN-104039396-A | PERSONAL CARE COMPOSITIONS COMPRISING A pH TUNEABLE GELLANT AND METHODS OF USING | PROCTER & GAMBLE | 2014-09-10 | — | — | CN | claimed |
| US-20130303427-A1 | MICROCAPSULE COMPOSITIONS COMPRISING pH TUNEABLE DI-AMIDO GELLANTS | THE PROCTER & GAMBLE COMPANY | 2013-11-14 | — | — | US | claimed |
| EP-2365053-A9 | Liquid detergent compositions comprising pH tuneable amido-gellants, and processes for making | The Procter & Gamble Company (US) | 2013-05-15 | — | — | EP | claimed |
| US-20110224124-A1 | pH Tuneable Amido-Gellant For Use In Consumer Product Compositions | THE PROCTER & GAMBLE COMPANY | 2011-09-15 | — | — | US | claimed |
| US-20110220537-A1 | Liquid Detergent Compositions Comprising pH Tuneable Amido-Gellants, and Processes For Making | THE PROCTER & GAMBLE COMPANY | 2011-09-15 | — | — | US | claimed |
| EP-2365052-A1 | pH tuneable-gellant for use in consumer product compositions | The Procter & Gamble Company (US) | 2011-09-14 | — | — | EP | claimed |
| EP-2365053-A1 | Liquid detergent compositions comprising pH tuneable amido-gellants, and processes for making | The Procter & Gamble Company (US) | 2011-09-14 | — | — | EP | claimed |
| EP-2365052-B1 | pH tuneable-gellant for use in consumer product compositions | PROCTER & GAMBLE (US) | 2016-07-13 | — | — | EP | disclosed |
| EP-2365053-B1 | Liquid detergent compositions comprising pH tuneable amido-gellants, and processes for making | PROCTER & GAMBLE (US) | 2016-04-27 | — | — | EP | disclosed |
| US-9271912-B2 | Personal care compositions comprising a pH tuneable gellant and methods of using | THE PROCTER & GAMBLE COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| EP-2365053-A9 | Liquid detergent compositions comprising pH tuneable amido-gellants, and processes for making | The Procter & Gamble Company (US) | 2013-05-15 | — | — | EP | disclosed |
| WO-2011112910-A1 | LIQUID DETERGENT COMPOSITIONS COMPRISING PH TUNEABLE AMIDO-GELLANTS, AND PROCESSES FOR MAKING | THE PROCTER & GAMBLE COMPANY (US) | 2011-09-15 | — | — | WO | disclosed |
| US-20110224124-A1 | pH Tuneable Amido-Gellant For Use In Consumer Product Compositions | THE PROCTER & GAMBLE COMPANY | 2011-09-15 | — | — | US | disclosed |
| US-20110224124-A1 | pH Tuneable Amido-Gellant For Use In Consumer Product Compositions | THE PROCTER & GAMBLE COMPANY | 2011-09-15 | — | — | US | disclosed |
| EP-2365052-A1 | pH tuneable-gellant for use in consumer product compositions | The Procter & Gamble Company (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-2365053-A1 | Liquid detergent compositions comprising pH tuneable amido-gellants, and processes for making | The Procter & Gamble Company (US) | 2011-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224124-A1 | pH Tuneable Amido-Gellant For Use In Consumer Product Compositions | AGPAT2, AGPAT5, GNAO1 | FAAH 36/4885SMN1; SMN2 2091/4885SLC6A5 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.